Compare Charles River Laboratories Intl. Inc (CRL) vs Centrus Energy Corp (LEU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Centrus Energy Corp — how do they compare? Charles River Laboratories Intl. Inc trades at $288.87 (market cap $13.46B), while Centrus Energy Corp trades at $185.61 (market cap $3.77B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 3.6× Centrus Energy Corp's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Centrus Energy Corp nearer its low. Which is the better fit depends on your goals.
| CRL | LEU | |
|---|---|---|
Market Cap | $13.46B | $3.77B |
Sector | Health | Energy |
52-Week High | $282.00 | $436.00 |
52-Week Low | $145.57 | $146.61 |
Enterprise Value | $16.30B | $3.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $284.37, up 2.66% today and near its 52-week high, reflecting strong bullish momentum. The stock has consistently beaten earnings estimates in recent quarters, including a Q2 2026 EPS of $3.02 versus $2.77 expected, and the company raised its full-year guidance. Despite negative net income margins, operating cash flow remains robust at $738 million in 2025. Analyst sentiment is overwhelmingly positive with 26 buy ratings and a consensus price target of $277.29.
The outlook is supported by improving biotech demand and cost controls, but high valuation multiples and recent insider selling pose risks. Earnings growth and margin expansion are key catalysts, though profitability challenges and macroeconomic sensitivity could pressure the stock. Investors should weigh strong technicals and analyst support against fundamental weaknesses and execution risks.
Centrus Energy (LEU) trades at $185.06, down 2.26% on the day, with a bullish technical signal from moving averages and a neutral RSI near 61. The stock shows strong earnings beats in Q1 and Q2 2026 but missed in Q4 2025, with revenue growth to $474 million in 2026. Recent news highlights a $4.5 billion backlog and a $1 billion DOE contract for nuclear fuel supply, positioning the company in the expanding nuclear energy sector.
Outlook is positive due to government support and contract wins, but risks include margin compression and high valuation multiples. Analysts maintain a buy consensus with a $228.50 price target, suggesting 23% upside, though execution on production goals by 2029 is critical for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Centrus Energy Corp
Centrus Energy is a leading supplier of nuclear fuel and services for the global power industry. It specializes in supplying low-enriched uranium and developing next-generation fuels for advanced nuclear reactors.
Read more on LEU →
